{"transactions":[{"id":1557657,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":92536,"kind":"person","name":"Krause Kevin Michael","position":1,"cik":"0001916925","reported_name":"Krause Kevin Michael","relationship":{"officer":true,"officer_title":"Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2024-03-29T20:17:22.000Z","date":"2024-03-15","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Previously reported on a Form 4 filed on March 18, 2024.  As amended, the vesting schedule for the restricted stock units is as follows: 1/4th of the shares vests annually over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date."}],"balance_after":31914,"source":{"system":"sec-edgar","filing":"0001610717-24-000193","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000161071724000193/form4.xml","form_type":"4/A","original_submission_date":"2024-03-18"}},{"id":1572710,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":92536,"kind":"person","name":"Krause Kevin Michael","position":1,"cik":"0001916925","reported_name":"Krause Kevin Michael","relationship":{"officer":true,"officer_title":"Chief Strategy Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-03-18T23:28:19.000Z","date":"2024-03-15","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date."}],"balance_after":60000,"derivative":{"exercise_price":3,"expiration_date":"2034-03-14","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001610717-24-000167","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000161071724000167/form4.xml","form_type":"4"}},{"id":1572709,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":92536,"kind":"person","name":"Krause Kevin Michael","position":1,"cik":"0001916925","reported_name":"Krause Kevin Michael","relationship":{"officer":true,"officer_title":"Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2024-03-18T23:28:19.000Z","date":"2024-03-15","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units vest as follows: 1/16th of the shares vests quarterly over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date."}],"balance_after":31914,"source":{"system":"sec-edgar","filing":"0001610717-24-000167","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000161071724000167/form4.xml","form_type":"4"}},{"id":1680875,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":92536,"kind":"person","name":"Krause Kevin Michael","position":1,"cik":"0001916925","reported_name":"Krause Kevin Michael","relationship":{"officer":true,"officer_title":"Chief Strategy Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-01-12T00:59:41.000Z","date":"2024-01-09","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from April 30, 2021, subject to the Reporting Person's continuous service as of such date."}],"balance_after":26832,"derivative":{"exercise_price":6.6,"expiration_date":"2031-04-29","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001610717-24-000027","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000161071724000027/form4.xml","form_type":"4"}},{"id":1680874,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":92536,"kind":"person","name":"Krause Kevin Michael","position":1,"cik":"0001916925","reported_name":"Krause Kevin Michael","relationship":{"officer":true,"officer_title":"Chief Strategy Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-01-12T00:59:41.000Z","date":"2024-01-09","kind":"exercise","planned":true,"acquired":false,"shares":2417,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option is subject to an early exercise provision and is immediately exercisable. The shares subject to the option vest as follows: 25% of the shares vested on November 21, 2020 and 1/48th of the shares vests monthly thereafter over the following three years, subject to the Reporting Person's continuous service as of such date."}],"balance_after":49868,"derivative":{"exercise_price":0.42,"expiration_date":"2030-01-22","underlying":"Common Stock","underlying_shares":2417},"source":{"system":"sec-edgar","filing":"0001610717-24-000027","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000161071724000027/form4.xml","form_type":"4"}},{"id":1680873,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":92536,"kind":"person","name":"Krause Kevin Michael","position":1,"cik":"0001916925","reported_name":"Krause Kevin Michael","relationship":{"officer":true,"officer_title":"Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2024-01-12T00:59:41.000Z","date":"2024-01-09","kind":"sale","planned":true,"acquired":false,"shares":7417,"price":20.1385,"value":149367.2545,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Price reported is a weighted-average sales price. The shares were sold at prices ranging from $20.00 to $20.33. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":1914,"source":{"system":"sec-edgar","filing":"0001610717-24-000027","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000161071724000027/form4.xml","form_type":"4"}},{"id":1680872,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":92536,"kind":"person","name":"Krause Kevin Michael","position":1,"cik":"0001916925","reported_name":"Krause Kevin Michael","relationship":{"officer":true,"officer_title":"Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2024-01-12T00:59:41.000Z","date":"2024-01-09","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":6.6,"value":33000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2023."}],"balance_after":9331,"source":{"system":"sec-edgar","filing":"0001610717-24-000027","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000161071724000027/form4.xml","form_type":"4"}},{"id":1680871,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":92536,"kind":"person","name":"Krause Kevin Michael","position":1,"cik":"0001916925","reported_name":"Krause Kevin Michael","relationship":{"officer":true,"officer_title":"Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2024-01-12T00:59:41.000Z","date":"2024-01-09","kind":"exercise","planned":true,"acquired":true,"shares":2417,"price":0.42,"value":1015.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2023."}],"balance_after":4331,"source":{"system":"sec-edgar","filing":"0001610717-24-000027","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000161071724000027/form4.xml","form_type":"4"}},{"id":1688341,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":92536,"kind":"person","name":"Krause Kevin Michael","position":1,"cik":"0001916925","reported_name":"Krause Kevin Michael","relationship":{"officer":true,"officer_title":"Chief Strategy Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-01-04T23:06:42.000Z","date":"2024-01-02","kind":"exercise","planned":true,"acquired":false,"shares":2583,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option is subject to an early exercise provision and is immediately exercisable. The shares subject to the option vest as follows: 25% of the shares vested on November 21, 2020; and 1/48th of the shares vests monthly thereafter over the following three years, subject to the Reporting Person's continuous service as of such date."}],"balance_after":52285,"derivative":{"exercise_price":0.42,"expiration_date":"2030-01-22","underlying":"Common Stock","underlying_shares":2583},"source":{"system":"sec-edgar","filing":"0001610717-24-000014","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000161071724000014/form4.xml","form_type":"4"}},{"id":1688340,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":92536,"kind":"person","name":"Krause Kevin Michael","position":1,"cik":"0001916925","reported_name":"Krause Kevin Michael","relationship":{"officer":true,"officer_title":"Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2024-01-04T23:06:42.000Z","date":"2024-01-02","kind":"sale","planned":true,"acquired":false,"shares":2583,"price":20.1189,"value":51967.1187,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Price reported is a weighted-average sales price. The shares were sold at prices ranging from $20.00 to $20.26. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":1914,"source":{"system":"sec-edgar","filing":"0001610717-24-000014","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000161071724000014/form4.xml","form_type":"4"}},{"id":1688339,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":92536,"kind":"person","name":"Krause Kevin Michael","position":1,"cik":"0001916925","reported_name":"Krause Kevin Michael","relationship":{"officer":true,"officer_title":"Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2024-01-04T23:06:42.000Z","date":"2024-01-02","kind":"exercise","planned":true,"acquired":true,"shares":2583,"price":0.42,"value":1084.86,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects the adjusted total which includes the purchase of 934 shares under the AN2 Employee Stock Purchase Plan on March 31, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects the adjusted total which includes the purchase of 980 shares under the AN2 Employee Stock Purchase Plan on September 29, 2023."}],"balance_after":4497,"source":{"system":"sec-edgar","filing":"0001610717-24-000014","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000161071724000014/form4.xml","form_type":"4"}},{"id":2008105,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":92536,"kind":"person","name":"Krause Kevin Michael","position":1,"cik":"0001916925","reported_name":"Krause Kevin Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Strategy Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-18T00:19:40.000Z","date":"2023-02-15","kind":"grant","acquired":true,"shares":62200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary as measured from January 1, 2023."}],"balance_after":62200,"derivative":{"exercise_price":14.29,"expiration_date":"2033-02-14","underlying":"Common Stock","underlying_shares":62200},"source":{"system":"sec-edgar","filing":"0000899243-23-005545","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924323005545/doc4.xml","form_type":"4"}},{"id":2270598,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":92536,"kind":"person","name":"Krause Kevin Michael","position":1,"cik":"0001916925","reported_name":"Krause Kevin Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Strategy Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-05-17T01:16:15.000Z","date":"2022-05-12","kind":"grant","acquired":true,"shares":66000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary as measured from March 25, 2022."}],"balance_after":66000,"derivative":{"exercise_price":17.28,"expiration_date":"2032-05-11","underlying":"Common Stock","underlying_shares":66000},"source":{"system":"sec-edgar","filing":"0000899243-22-018278","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322018278/doc4.xml","form_type":"4"}}]}